Business
Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights
Continued to make significant progress advancing BMF-219, the company’s lead investigational orally administered covalent menin inhibitor, in multiple
About this update from Biomea Fusion, Inc.
[{"type":"text","content":"Continued to make significant progress advancing BMF-219, the company’s lead investigational orally administered covalent menin inhibitor, in multiple oncology indications COVALENT-101 (Phase I) study is enrolling for patients with Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Diffuse Large B-cell Lymphoma (DLBCL), and Multiple Myeloma (MM)On track to submit IND for BMF-219 in solid tumors, including non-small cell lung cancer, colorectal cancer and pancreatic cancer in the fourth quarter of 2022New preclinical ex vivo and validation data for BMF-219 underlying the company’s oncology clinical development strategy presented at the 2022 annual meetings of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), respectively Expanded clinical development strategy for BMF-219 to include type 2 diabetes New preclinical in vivo data for BMF-219 underlying the company’s innovative approach to treat type 2 diabetes with covalent menin inhibition presented at the American Diabetes Association (ADA) Scientific Sessions 2022On track to submit IND for BMF-219 in type 2 diabetes in the second half of 2022Upcoming two oral presentations at the 2022 annual meeting of the European Association for the Study of Diabetes (EASD) in September Announced selection of second IND candidate, BMF-500, a potential best-in-class, oral, covalent inhibitor of FLT3 with picomolar potency against aggressive leukemia cell modelsCash position of $150.2 million at the end of the second quarter of 2022 REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported second quarter 2022 financial results and business highlights. “The team continues to deliver against critical corporate goals as we look to build tremendous value potential for the company in the near and long-term. During the second quarter, we focused specifically on key clinical operations and clinical science activities to support COVALENT-101. Additionally, we continued to design and execute key experiments to support our diabetes effort as we march towards the clinic,” said Thomas Bu...